Sugi Predict

Sugi Predict / Compounds / SCHEMBL5210248

SCHEMBL5210248

SCHEMBL5210248

C#CCNC(=O)c1ccccc1Nc1ccc2c(C(=O)NC)nn(C3CCCCO3)c2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.43
▸ INSR P06213 1/20 0.38
▸ MET P08581 1/20 0.38
▸ MAPK10 P53779 1/20 0.37
▸ DGAT2 Q96PD7 1/20 0.36
▸ VCP P55072 2/20 0.33
▸ RCE1 Q9Y256 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ HTR4 Q13639 2/20 0.33
▸ MAPK3 P27361 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GRM4 Q14833 3/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ POLR1A O95602 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210343 0.88 MAPK10 (0.39) MAPK10DGAT2MAPK3MAPK1GRM4
SCHEMBL5209747 0.86 KDM4E (0.41) MAPK10DGAT2NPC1ALDH1A1RAB9A
SCHEMBL5210274 0.81 KDR (0.48) KDRINSRMETDGAT2VCP
SCHEMBL5209155 0.81 KDR (0.53) KDRINSRMETMAPK10DGAT2
SCHEMBL6185649 0.80 KDR (0.51) KDRINSRMETMAPK10DGAT2
SCHEMBL5211276 0.79 KDM4E (0.43) DGAT2ALDH1A1SMN1; SMN2
SCHEMBL5207781 0.78 MAPT (0.42) DGAT2ALDH1A1SMN1; SMN2
SCHEMBL6207155 0.77 ELANE (0.43) MAPK1ALDH1A1
SCHEMBL5210223 0.75 KDR (0.45) KDRMAPK10DGAT2RCE1EGFR
SCHEMBL5213440 0.74 KDR (0.44) KDRMAPK10DGAT2RCE1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 — — EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 — — US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 — — US disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 KDR 88/4885INSR 181/4885MET 734/4885
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 KDR 88/4885INSR 181/4885MET 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.